0001437749-23-016311.txt : 20230601 0001437749-23-016311.hdr.sgml : 20230601 20230531192447 ACCESSION NUMBER: 0001437749-23-016311 CONFORMED SUBMISSION TYPE: SD PUBLIC DOCUMENT COUNT: 1 13p-1 1.01 20221231 FILED AS OF DATE: 20230601 DATE AS OF CHANGE: 20230531 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NAVIDEA BIOPHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000810509 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 311080091 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SD SEC ACT: 1934 Act SEC FILE NUMBER: 001-35076 FILM NUMBER: 23982640 BUSINESS ADDRESS: STREET 1: 4995 BRADENTON AVENUE STREET 2: SUITE 240 CITY: DUBLIN STATE: OH ZIP: 43017 BUSINESS PHONE: 6147937500 MAIL ADDRESS: STREET 1: 4995 BRADENTON AVENUE STREET 2: SUITE 240 CITY: DUBLIN STATE: OH ZIP: 43017 FORMER COMPANY: FORMER CONFORMED NAME: NEOPROBE CORP DATE OF NAME CHANGE: 19940714 SD 1 navb20230531_sd.htm FORM SD navb20230531_sd.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM SD

Specialized Disclosure Report

 

 

NAVIDEA BIOPHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

  

001-35076

  

31-1080091

(State or other jurisdiction

of incorporation or organization)

  

(Commission File Number)

  

(IRS Employer Identification No.)

 

4995 Bradenton Avenue, Suite 240, Dublin, Ohio

  

43017

(Address of principal executive offices)

  

(Zip Code)

 

Joseph Meyer, (614) 793-7500

(Name and telephone number, including area code, of the person to contact in connection with this report.)

 

 

Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

 

☒

Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2022.

 

 
 

 

Section 1 – Conflict Minerals Disclosure

 

Item 1.01 Conflict Minerals Disclosure

 

Navidea Biopharmaceuticals, Inc. (the Company) has evaluated its current product line to determine whether it manufactures or contracts to manufacture any products for which columbite‑tantalite (colta), cassiterite, gold, wolframite, or their derivatives are necessary to the functionality of the product. The Company has determined that its technetium Tc 99m tilmanocept injection product (the Covered Product) contains tin, a derivative metal from the mineral cassiterite.

 

The Company has conducted a reasonable country of origin inquiry (RCOI) as required by the Dodd-Frank Wall Street Reform and Consumer Protection Act. The Company’s RCOI consisted of submitting inquiries to its supplier of the Covered Product. The Company has relied on the certification from an upstream supplier of its supplier that the tin used in the Covered Product did not originate from the Democratic Republic of Congo or an adjoining country.  The Company has no reason to believe that this certification is inaccurate. Accordingly, the Company has determined that the tin contained in the Covered Product did not originate from the Democratic Republic of Congo or an adjoining country.

 

A copy of this Conflict Minerals Disclosure is publicly available at www.navidea.com under “Investors,” then “Corporate Governance,” then “Governance Documents,” then “Conflict Minerals Disclosure.”

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

 

     

Navidea Biopharmaceuticals, Inc.

    

(Registrant)

    
     
     

/s/ Joseph W. Meyer

  

May 31, 2023

By (Signature and Title)

  

(Date)

Joseph W. Meyer

    

Director, Finance and Accounting

    

(Principal Financial Officer)